Literature DB >> 19909407

Enamel matrix derivative induces the expression of tissue inhibitor of matrix metalloproteinase-3 in human gingival fibroblasts via extracellular signal-regulated kinase.

E Zeldich1, R Koren, M Dard, E Weinberg, M Weinreb, C E Nemcovsky.   

Abstract

BACKGROUND AND
OBJECTIVE: Periodontal disease is characterized by increased expression and activity of matrix metalloproteinases (MMPs) and insufficient expression/activity of their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMPs). This altered MMP-TIMP balance results in progressive destruction of gingival and periodontal extracellular matrix. Enamel matrix derivative (EMD), clinically used for periodontal regeneration in a device called Emdogain, has been suggested to enhance gingival healing following periodontal procedures in humans. We previously showed that EMD increases the proliferation of human and rat gingival fibroblasts and protects them from tumor necrosis factor-induced apoptosis. In the present study, the modulation of MMP and TIMP expression by EMD was investigated.
MATERIAL AND METHODS: Primary human gingival fibroblasts were treated in vitro with tumor necrosis factor, EMD or both in serum-free conditions, and RNA was analyzed with an extracellular matrix-focused microarray and quantitative real-time polymerase chain reaction.
RESULTS: Microarray analysis showed detectable expression of MMP-1, MMP-2, MMP-3, MMP-7 and MMP-13, as well as TIMP-1 and TIMP-3 in untreated cells. There was no apparent regulation of the expression of MMP-2, MMP-7, MMP-13 and TIMP-1 by either tumor necrosis factor or EMD. In contrast, tumor necrosis factor significantly increased MMP-1 expression, and EMD reduced it when both agents were present. Also, EMD significantly induced TIMP-3 expression, an effect which was dependent on activation of extracellular signal-regulated kinase 1/2, since it was totally abolished by a selective extracellular signal-regulated kinase pathway inhibitor.
CONCLUSION: These data suggest that EMD may affect gingival health by ways other than cell proliferation/survival, i.e. by stimulation of TIMP-3 production, which could improve the MMP-TIMP balance in gingival tissue and curb extracellular matrix destruction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909407     DOI: 10.1111/j.1600-0765.2009.01218.x

Source DB:  PubMed          Journal:  J Periodontal Res        ISSN: 0022-3484            Impact factor:   4.419


  6 in total

1.  Enamel matrix derivative promotes superoxide production and chemotaxis but reduces matrix metalloproteinase-8 expression by polymorphonuclear leukocytes.

Authors:  Mamdouh M Karima; Thomas E Van Dyke
Journal:  J Periodontol       Date:  2011-11-03       Impact factor: 6.993

2.  Porphyromonas gingivalis Lipopolysaccharide Induces a Pro-inflammatory Human Gingival Fibroblast Phenotype.

Authors:  S Buket Bozkurt; Sema S Hakki; Erdogan E Hakki; Yusuf Durak; Alpdogan Kantarci
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

3.  IL-1β promotes ADAMTS enzyme-mediated aggrecan degradation through NF-κB in human intervertebral disc.

Authors:  Zhongyi Sun; Zhanmin Yin; Chao Liu; He Liang; Minbo Jiang; Jiwei Tian
Journal:  J Orthop Surg Res       Date:  2015-10-06       Impact factor: 2.359

4.  Human gingival fibroblast response to enamel matrix derivative, porcine recombinant 21.3-kDa amelogenin and 5.3-kDa tyrosine-rich amelogenin peptide.

Authors:  Marzena Wyganowska-Swiatkowska; Paulina Urbaniak; Daniel Lipinski; Marlena Szalata; Malgorzata Kotwicka
Journal:  Hum Cell       Date:  2017-05-03       Impact factor: 4.174

5.  Enamel matrix protein derivatives: role in periodontal regeneration.

Authors:  Vandana J Rathva
Journal:  Clin Cosmet Investig Dent       Date:  2011-12-01

6.  A retrospective analysis of factors influencing the success of autotransplanted posterior teeth.

Authors:  Mirco F Ronchetti; Silvio Valdec; Nikolaos Pandis; Michael Locher; Hubertus van Waes
Journal:  Prog Orthod       Date:  2015-11-23       Impact factor: 2.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.